Recently, two back-to-back RCTs including SORMAIN and our own have demonstrated that sorafenib maintenance can prevent relapse and improve survival for patients with FLT3-ITD AML following allo-​HSCT [35, 36]. Here, FLT3 is linked to acute myeloid leukemia.